Anti-HIV antibody and method for producing the same
Producing anti-HIV antibodies in silkworms using silk gland-specific promoters addresses inefficiencies in existing methods, achieving high efficiency and long-term virus suppression by leveraging antibodies without fucose in their sugar chains.
Patent Information
- Application Number
- JP2024140929
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-09-12
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for producing anti-HIV antibodies are inefficient and lack the ability to achieve long-term virus suppression with high probability through single or few administrations, and existing antibodies do not effectively suppress HIV to below the detection limit for an extended period.
The production of anti-HIV antibodies, such as 1C10 and 1D9, in silkworms using a silk gland-specific promoter, which results in antibodies lacking fucose in their sugar chains, enabling high efficiency and long-term virus suppression with a high probability through single or few administrations.
The antibodies produced in silkworms demonstrate excellent ADCC activity and can suppress HIV to below the detection limit in all treated animals for a long period, exceeding 12 weeks, with a high success rate.
Smart Images

Figure 2024161579000005 
Figure 2024161579000006 
Figure 2024161579000007
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This international application claims priority based on Japanese Patent Application No. 2018-203114 filed with the Japan Patent Office on October 29, 2018, and Japanese Patent Application No. 2019-166040 filed with the Japan Patent Office on September 12, 2019, the entire contents of which are incorporated by reference into this international application. [Technical field]
[0002] The present invention relates to a method for efficiently producing an anti-HIV antibody. More specifically, the present invention relates to a method for highly efficiently producing an anti-HIV antibody using silkworms. [Background technology]
[0003] Attempts have been made to produce therapeutic antibodies in silkworms by placing an antibody gene downstream of the silkworm sericin promoter and expressing the antibody molecule in the cocoon (Non-Patent Documents 1 and 2, etc.). In particular, antibodies expressed in silkworm cocoons are known to exhibit excellent ADCC activity because the sugar chain does not contain core fucose (Patent Documents 1 and 2).
[0004] In addition, in HIV treatment strategies, it is expected that antibodies that can control HIV for a long period of time after a single or multiple administrations of the antibody will be developed. For example, Non-Patent Document 3 reports that, of four rhesus monkeys that received a single dose of PGT121, one had viral RNA suppressed below the detection limit for approximately 70 days.
[0005] In addition, KD247, a humanized antibody that recognizes the V3 loop of gp120, an HIV envelope protein, has been developed and clinical trials are currently underway. Although viral suppression was confirmed in patients who received three doses of KD247, the virus was not suppressed below the detection limit for a long period of time. Thus, an antibody that can suppress the virus below the detection limit for a long period of time with a high probability by administering it once or several times as a single drug has not yet been developed.
[0006] Therefore, the development of 1C10 antibody, a human antibody that has the same antigen recognition site as KD247, is underway. The 1C10 antibody was isolated from a patient who possesses antibodies capable of neutralizing a wide range of HIV strains in his body and whose symptoms have been suppressed without treatment for a long period of time (over 25 years), and is expected to have a high therapeutic effect when administered to HIV-infected patients as an antibody drug (Patent Document 2 and Non-Patent Document 4). [Prior art documents] [Patent documents]
[0007] [Patent Document 1] Patent Publication No. 2014-12024 [Patent Document 2] International Publication No. WO2009 / 066702 [Non-patent literature]
[0008] [Non-Patent Document 1] Masashi Iizuka,et al.,FEBS Journal;276:5806-5820(2009) [Non-Patent Document 2] Minoru Toda,et al.,mABs;7(6):1138-1150(2015) [Non-Patent Document 3] Dan H. Barouch,et al.,Nature;503(7475):224-228(2013) [Non-Patent Document 4] Kristel Paola Ramirez Valdez,et al.,Virology;475:187-203(2015) Summary of the Invention
[0009] The present inventors have conducted extensive research into antibodies that can provide long-term HIV virus control in a single administration or several times, and have surprisingly found that a few times of single administration of SW-1C10 antibody, obtained by producing the antibody gene reported as 1C10 in silkworms, not only suppressed the virus in the blood to below the detection limit in all administered individuals, but also maintained the viral RNA in the blood below the detection limit for as long as 12 weeks. Furthermore, the inventors compared the antibody produced in silkworms with the antibody produced in CHO cells and confirmed that the structural difference between them lies in the sugar chain structure. From this, the inventors have found that deleting fucose brings about an extremely excellent effect of long-term virus suppression in all administered cases of the 1C10 antibody. There have been no reports in the past that such long-term virus proliferation control is possible in all administered cases, and the inventors have succeeded in finding an antibody that can provide widespread and stable virus suppression in administered subjects by a few times of single administration for the first time.
[0010] Furthermore, until now, the amount of antibodies produced by silkworms has been several hundred μg per cocoon, or a few μg per mg of cocoon, and no attempt has been made to further increase productivity. The inventors conducted extensive research to find an antibody that is produced in higher amounts in silkworms from among the many anti-HIV antibodies, and discovered that the anti-HIV antibodies 1C10 and 1D9 are produced in silkworm silk in amounts superior to conventional production amounts, thus completing the present invention.
[0011] Thus, in one aspect, the present invention relates to an antibody that has the ability to bind to HIV; and the sugar chain bound to the antibody does not contain fucose; and has the effect of suppressing HIV in the blood of an HIV-infected person to below the detection limit with a probability of 90% or more by a single administration or several administrations to the HIV-infected person. Methods for examining whether or not a certain antibody has the ability to bind to HIV are widely known in the art. For example, it can be confirmed by contacting the antibody with a carrier on which HIV is immobilized and detecting the antibody bound to the solid phase.
[0012] In one aspect, the present invention relates to an IgG antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 7, an amino acid sequence having 80% or more identity thereto, or an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 9, an amino acid sequence having 80% or more identity thereto, or an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted; having the ability to bind to HIV; and wherein the glycan that binds to the antibody does not contain fucose.
[0013] Preferably, the antibody of the present invention has a heavy chain having three CDR sequences in the heavy chain amino acid sequence set forth in SEQ ID NO:7, and a light chain having three CDR sequences in the amino acid sequence set forth in SEQ ID NO:9. The CDR sequences can be determined using the numbering system of Kabat et al. (Kabat, E. et al., US Department of Health and Human Services, (1983) and its successors), the numbering system of Chothia et al. (Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)), the numbering system of Honegger et al. (Honegger, A et al., J. Mol. Biol. 309:657-670 (2001)), the contact definition method (MacCallum et al., J Mol Biol, 262(5):732-745 (1996)), the numbering system according to the IMGT database (http: / / www.imgt.org / ), or by alignment to known sequence databases. For example, the CDR sequences of the antibody of the present invention may be CDRH1: GFMFSNYA (SEQ ID NO: 14); CDRH2: ISNDGSDK (SEQ ID NO: 15); CDRH3: CARDLDQTIPDLTAPAFEV (SEQ ID NO: 16), and CDRL1: QSLLHSDGNN (SEQ ID NO: 17); CDRL2: LTS (SEQ ID NO: 18); CDRL3: MQSLQTWT (SEQ ID NO: 19). More preferably, the antibody of the present invention has a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 7, and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 9.
[0014] The antibody of the present invention does not contain fucose in the sugar chain to which it is bound. For example, the antibody of the present invention may have a sugar chain structure selected from the following:
[0015] [ka] In one aspect, the present invention relates to an expression cassette comprising any one of the following polynucleotides (i) to (x), operably linked downstream of a silk gland-specific gene promoter: (i) a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 6 and / or the nucleotide sequence set forth in SEQ ID NO: 8; (ii) a polynucleotide having a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence set forth in SEQ ID NO: 6, and / or a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence set forth in SEQ ID NO: 8; (iii) a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 7, and / or a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 9; (iv) a polynucleotide encoding an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO: 7, and / or a polynucleotide encoding an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO: 9; (v) a polynucleotide encoding an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted in the amino acid sequence set forth in SEQ ID NO: 7, and / or a polynucleotide encoding an amino acid sequence in which several amino acids have been substituted, deleted, added, or inserted in the amino acid sequence set forth in SEQ ID NO: 9; (vi) a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 10 and / or the nucleotide sequence set forth in SEQ ID NO: 12; (vii) a polynucleotide having a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence set forth in SEQ ID NO: 10, and / or a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence set forth in SEQ ID NO: 12; (viii) a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 11, and / or a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 13; (ix) a polynucleotide encoding an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO: 11, and / or a polynucleotide encoding an amino acid sequence having 80% or more identity to the amino acid sequence set forth in SEQ ID NO: 13; and (x) A polynucleotide encoding an amino acid sequence in which several amino acids have been substituted, deleted, added, or inserted in the amino acid sequence set forth in SEQ ID NO: 11, and / or a polynucleotide encoding an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted in the amino acid sequence set forth in SEQ ID NO: 13.
[0016] In the present specification, the 1C10 antibody is an antibody having a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 9. In addition, the first to the nineteenth amino acids in the amino acid sequence set forth in SEQ ID NO: 7 are a signal sequence. The heavy and / or light chains of the antibody described herein may not contain the signal sequence described herein. Alternatively, they may contain a signal sequence other than the signal sequence described herein. Therefore, in the present specification, the term "heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 7" may be appropriately read as "heavy chain consisting of the amino acid sequence from the 20th to the 474th amino acid sequence of SEQ ID NO: 7". Similarly, in the amino acid sequence set forth in SEQ ID NO: 9, the first to the 20th amino acids are a signal sequence. Therefore, in the present specification, the term "light chain consisting of the amino acid sequence set forth in SEQ ID NO: 9" may be appropriately read as "light chain consisting of the amino acid sequence from the 21st to the 238th amino acid sequence of SEQ ID NO: 9". In addition, in the present specification, the 1D9 antibody is an antibody having a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 11 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 13. In addition, of the amino acid sequence described in SEQ ID NO:11, the first to nineteenth positions are a signal sequence. Therefore, in this specification, the term "heavy chain consisting of the amino acid sequence described in SEQ ID NO:11" may be appropriately read as "heavy chain consisting of the amino acid sequence from the 20th to the 472nd positions of SEQ ID NO:11". Similarly, of the amino acid sequence described in SEQ ID NO:13, the first to the 20th positions are a signal sequence. Therefore, in this specification, the term "light chain consisting of the amino acid sequence described in SEQ ID NO:13" may be appropriately read as "light chain consisting of the amino acid sequence from the 21st to the 238th positions of SEQ ID NO:9".
[0017] Examples of DNA sequences encoding the 1C10 antibody include the nucleotide sequence (heavy chain) shown in SEQ ID NO: 6 and the nucleotide sequence (light chain) shown in SEQ ID NO: 8. As described above, in the nucleotide sequence (heavy chain) shown in SEQ ID NO: 6, 57 bases encode a signal sequence. Therefore, in this specification, the term "nucleotide sequence shown in SEQ ID NO: 6" may be appropriately interpreted as "the nucleotide sequence from the 58th to the 1425th bases of the nucleotide sequence shown in SEQ ID NO: 6". Similarly, in the nucleotide sequence (light chain) shown in SEQ ID NO: 8, 60 bases encode a signal sequence. Therefore, in this specification, the term "nucleotide sequence shown in SEQ ID NO: 8" may be appropriately interpreted as "the nucleotide sequence from the 61st to the 717th bases of the nucleotide sequence shown in SEQ ID NO: 8". In addition, examples of DNA sequences encoding the 1D9 antibody include the nucleotide sequence (heavy chain) shown in SEQ ID NO: 10 and the nucleotide sequence (light chain) shown in SEQ ID NO: 12. As described above, in the nucleotide sequence (heavy chain) shown in SEQ ID NO: 10, 57 bases encode a signal sequence. Therefore, in this specification, the term "the base sequence described in SEQ ID NO:10" may be appropriately read as "the base sequence from base 58 to base 1419 of the base sequence described in SEQ ID NO:10." Similarly, of the base sequence (light chain) described in SEQ ID NO:12, base 60 codes for a signal sequence. Therefore, in this specification, the term "the base sequence described in SEQ ID NO:12" may be appropriately read as "the base sequence from base 61 to base 717 of the base sequence described in SEQ ID NO:12."
[0018] In this specification, "hybridizing under stringent conditions" means hybridizing under hybridization conditions commonly used by those skilled in the art. For example, whether or not hybridization occurs can be determined by the method described in Molecular Cloning, a Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press (2012) or Current Protocols in Molecular Biology, Wiley Online Library, etc. For example, the hybridization conditions may be hybridization at 42°C in 6×SSC (0.9M NaCl, 0.09M trisodium citrate) or 6×SSPE (3M NaCl, 0.2M NaH2PO4, 20mM EDTA·2Na, pH 7.4), followed by washing with 0.5×SSC at 42°C.
[0019] In one aspect, the present invention relates to a polynucleotide encoding an amino acid sequence having 80% or more identity with each of the amino acid sequence set forth in SEQ ID NO: 7 and the amino acid sequence set forth in SEQ ID NO: 9, or the amino acid sequence set forth in SEQ ID NO: 11 and the amino acid sequence set forth in SEQ ID NO: 13 (referred to as "the amino acid sequence set forth in SEQ ID NO: 7, etc." in this paragraph). The identity of an amino acid sequence means the percentage (%) of the number of amino acids whose types are the same in the range of amino acid sequences to be compared between two types of proteins, and can be determined using known programs such as BLAST and FASTA. The identity may be higher than 80% or more, and may be, for example, 85% or more, 90% or more, 95% or more, 98% or more, or 99% or more. Alternatively, the polynucleotide of the present invention may be a polynucleotide encoding an amino acid sequence showing a homology score of 200 or more with the amino acid sequence set forth in SEQ ID NO: 7, etc. in Blast. The homology score can be calculated by aligning the amino acid sequence described in SEQ ID NO: 7 etc. with the amino acid sequence of the target protein, determining the scores of each amino acid to be compared from a score matrix, and then calculating the sum of the scores (see http: / / www.gsic.titech.ac.jp / supercon / supercon2004-e / alignmentE.html). For example, the homology score can be determined using a known BLAST program. Known score matrices include BLOSUM62 and PAM32, and BLOSUM62 is preferred in this specification.
[0020] The number of amino acids to be substituted, deleted, added, and / or inserted is not particularly limited as long as it does not affect the biological activity of the antibody, and may be, for example, 1 to 10, 1 to 5, 1 to 4, or 1 to 3. The amino acid substitution is preferably a substitution between conservative amino acids (see Molecular Biology of the Cell, Garland Science; 6th Edition).
[0021] The term "silk gland-specific gene promoter" refers to a promoter of a gene that is specifically expressed in the silk gland of a silkworm. Examples of such promoters include silk protein gene promoters, such as a posterior silk gland-specific gene promoter and a middle silk gland-specific gene promoter, and the like, such as a sericin gene promoter (sericin 1 gene promoter, sericin 2 gene promoter, and sericin 3 gene promoter) or a fibroin gene promoter (fibroin heavy chain gene promoter, fibroin light chain gene promoter, and fibrohexamerin promoter). Preferred are the sericin 1 gene promoter, sericin 2 gene promoter, and sericin 3 gene promoter, including the MSG promoter and the PSG promoter (WO2017135452A1). Functionally linked downstream of a promoter means that the linked gene is linked so that it can be expressed by activating the promoter.
[0022] In another aspect, the present invention relates to a plasmid vector containing the expression cassette. The plasmid vector is not particularly limited as long as it can be introduced into and maintained in silkworm cells. For example, a plasmid vector incorporating the DNA transposon piggyBac derived from Trichoplusia ni (Tamura, T et al., Nature Biotechnology, 18:81-84 (2000)) can be mentioned. For example, vectors include pPIGA3GFP (Tamura, T et al., Nature Biotechnology, 18:81-84 (2000)) and pBac[3xP3-DsRed / pA] (Nature Biotechnology, 21:52-56 (2003)). The vector of the present invention can also be prepared by inserting the expression cassette into a restriction enzyme cleavage site of a vector (pMSG1.1MG) prepared by the method described in U.S. Patent Publication 2008 / 0301823. Alternatively, for example, the vector may be the silkworm transformation vector pMSG3.1MG (JP Patent Publication No. 2012-182995).
[0023] In one embodiment, the present invention relates to a transgenic silkworm in which the expression cassette is incorporated into a chromosome. In this specification, the term "silkworm" is not particularly limited as long as it is an insect that has a silk gland and can spin silk threads, and refers to a species of insects in the order Lepidoptera, Hymenoptera, Nervipidae, and Trichoptera that spin silk threads mainly in the larval stage for nesting, cocooning, or movement. As the silkworm, a Lepidoptera insect that can spin a large amount of silk threads is preferable, and examples thereof include species belonging to the families Bombycidae, Saturniidae, Pycnonotidae, Arctiidae, and Noctuidae. In addition, the silkworm includes Bombyx mori, Bombyx mori, Cynthia serrata, Siberian stag beetle ... The transgenic silkworm of the present invention produces (secretes) the antibody in the silk thread (cocoon) (preferably, the sericin layer).
[0024] In another aspect, the present invention relates to an antibody produced by said transgenic silkworm. The antibody may comprise a heavy chain having the amino acid sequence set forth in SEQ ID NO:7 and / or a light chain having the amino acid sequence set forth in SEQ ID NO:9, or a heavy chain having the amino acid sequence set forth in SEQ ID NO:11 and / or a light chain having the amino acid sequence set forth in SEQ ID NO:13. Alternatively, the antibody may comprise a heavy chain and / or a light chain having an amino acid sequence having 80% or more identity with SEQ ID NO:7 and / or SEQ ID NO:9, or SEQ ID NO:11 and / or SEQ ID NO:13, respectively. Alternatively, the antibody of the present invention may have a heavy chain and / or a light chain having an amino acid sequence showing a Blast homology score of 200 or more with SEQ ID NO:7 and / or SEQ ID NO:9, or SEQ ID NO:11 and / or SEQ ID NO:13, respectively. Alternatively, the antibody of the present invention may have a heavy chain and / or a light chain consisting of an amino acid sequence in which several amino acids are substituted, deleted, added, and / or inserted in SEQ ID NO:7 and / or SEQ ID NO:9, or SEQ ID NO:11 and / or SEQ ID NO:13, respectively. Furthermore, as used herein, the term "antibody" may refer to a portion, fragment, or modified form of an antibody, as long as it contains Fc and an antigen-binding site, and may be, for example, a single-chain antibody (e.g., a heavy-chain antibody) or a bispecific antibody.
[0025] It is known that antibodies produced in silkworm cocoons do not have fucose bound to them as sugar chains. It is also widely known in the art that antibodies without fucose have excellent ADCC activity. There have been no reports of ADCC activity and virus suppression by antibody administration, but it is possible that such effects of the present invention are brought about by ADCC activity. Thus, in one aspect, the present invention is an IgG antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 7, an amino acid sequence having 80% or more identity thereto, or an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 9, an amino acid sequence having 80% or more identity thereto, or an amino acid sequence in which several amino acids have been substituted, deleted, added, and / or inserted; having the ability to bind to HIV; and a composition comprising an antibody in which the Fc region has been modified to improve ADCC activity, wherein the ADCC activity is higher than that of a wild-type antibody produced in CHO cells, and the composition may comprise an anti-HIV antibody composition having the effect of suppressing HIV in the blood of an HIV-infected person to below the limit of detection with a probability of 90% or more after a single administration or several administrations to the HIV-infected person.
[0026] It has also been shown that the relationship between Fc and FcγR affects ADCC activity, and it has been reported that the affinity with FcγR can be increased by amino acid substitution in the Fc region. In particular, Fc that binds well to activating FcγR such as FcγRIIIa and weakly to inhibitory FcγR such as FcγRIIb is known to have superior effector function. Such mutations include F158V, A330L, S239D, and I332E (Greg ALazar et al., PNAS (2006) 103 (11): 4005-4010), and F243L, D270E, R292P, S298N, Y300L, V305I, A330V, and P396L (Cancer Res (2007) 67 (18): 8882-8890). The Fc region of the antibody of the present invention may have such mutations, for example, 1 to 10 mutations selected from A330L, S239D, I332E, F243L, D270E, R292P, S298N, Y300L, V305I, A330V, and P396L.
[0027] In another aspect, the present invention relates to a composition comprising an IgG antibody capable of binding to HIV, in which 80% or more of the IgG antibody does not contain fucose in the antibody-bound sugar chain. That is, in the composition of the present invention, it is not necessary that all (100%) anti-HIV antibodies do not contain fucose, but at least 80% or more (preferably 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more) of the anti-HIV antibodies do not contain fucose. Preferably, the composition has an effect of suppressing HIV in the blood of an HIV-infected person to below the detection limit with a probability of 90% or more by a single administration or several administrations to the HIV-infected person. The characteristics of the anti-HIV antibody of the composition, such as the sequence, are the same as those of the anti-HIV antibody of the present invention.
[0028] In this specification, whether or not "a single administration or multiple administrations to an HIV-infected person has the effect of suppressing HIV in the blood of the HIV-infected person to below the detection limit with a probability of 90% or more (preferably 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%)" can be confirmed by administering the test antibody to multiple HIV-infected people and then detecting HIV in their blood by a standard method, for example, a method using PCR. If HIV is not detected in the blood of 90% or more of the HIV patients who have been administered the test antibody, it can be determined that the test antibody has the effect of suppressing HIV in the blood of the HIV-infected person to below the detection limit with a probability of 90% or more when administered to the HIV-infected person. It is desirable to determine whether HIV in the blood has been suppressed below the limit of detection after all antibody administration has been completed, and preferably this can be done 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 1 year, 2 years, 3 years, 4 years, or 5 years after completion of administration.
[0029] In yet another aspect, the present invention relates to a therapeutic or prophylactic agent (pharmaceutical composition) for HIV infection, containing the above-mentioned antibody as an active ingredient. The pharmaceutical composition of the present invention may be any oral or parenteral formulation that can be administered to a patient. Examples of compositions for parenteral administration include injections, nasal drops, suppositories, patches, ointments, etc. Preferably, the pharmaceutical composition is an injection. Examples of the dosage form of the pharmaceutical composition of the present invention include liquids or freeze-dried preparations. When the pharmaceutical composition of the present invention is used as an injection, additives such as solubilizing agents such as propylene glycol and ethylenediamine, buffers such as phosphates, isotonic agents such as sodium chloride and glycerin, stabilizers such as sulfites, preservatives such as phenol, and soothing agents such as lidocaine (see "Dictionary of Pharmaceutical Additives" Yakuji Nipposha, "Handbook of Pharmaceutical Excipients Fifth Edition" APhA Publications) can be added as necessary. Furthermore, when the pharmaceutical composition of the present invention is used as an injection, examples of storage containers include ampoules, vials, prefilled syringes, cartridges for pen-type syringes, and infusion bags. Effect of the Invention
[0030] Since the antibody of the present invention can be produced with high efficiency using silkworms, it is possible to provide an antibody for treating HIV infection that can be produced at lower production costs. [Brief description of the drawings]
[0031] [Figure 1] The photographs show the expression levels of transgenic silkworms compared by CBB staining after SDS-PAGE. A: total extract; B: neutral buffer extract. The numbers on the left side of the photographs indicate the molecular weight (kDa), and the top of the photographs indicate the type of antibody used. [Diagram 2] 1 is a graph showing the results of measuring the binding activity of each antibody produced by transgenic silkworms against the HIV-1 BaL strain. The vertical axis shows the mean fluorescence intensity (MFI), and the horizontal axis shows the antibody concentration (μg / mL). [Diagram 3] This is a graph showing the results of measuring the neutralizing activity of antibodies of different origins against the HIV-1 BaL strain. The vertical axis shows the inhibition rate (% inhibition), and the horizontal axis shows the antibody log concentration (μg / mL). The table below shows the inhibition rate (% inhibition) for each antibody at each concentration. [Figure 4] The results of estimating the glycan structures of antibodies expressed in silkworm cocoons and antibodies produced in CHO cells from mass spectrometry are shown below. The main glycan structures and their abundance ratios are shown. [Diagram 5] Graph (A) and table (B) show the results of measuring ADCC activity when SW-1C10, 293A-1C10, CHO-1C10, and KD-247 were added to the HIV-1 BaL strain at 0.2, 2, and 20 μg / mL. SW-1C10 had the highest ADCC activity, followed by CHO-1C10. [Figure 6] This graph shows the results of administering SW-1C10 to cynomolgus monkeys inoculated with the highly virulent SHIV89.6P (Reimann KA et al., J. Virol. 70, 6922-6928.) in order to evaluate the efficacy of SW-1C10 during the acute infection phase. The graph on the left shows the SW-1C10 administration group (n=3), and the graph on the right shows the untreated group (n=2). The vertical axis of the upper graph shows the number of viral RNA copies in 1 ml of plasma (log10 copies / mL), and the vertical axis of the lower graph shows the number of CD4+ T cells (count / μL). Systemic infection was established. The horizontal axis of all graphs shows the time (weeks) elapsed after viral infection. SW-1C10 was administered intravenously on days 3, 10, and 17 after viral inoculation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] 1. Antibodies In one aspect, the present invention includes a method for producing an antibody of the present invention, which comprises expressing an antibody gene of the present invention in a silkworm, and an antibody produced by the method. Specifically, the production method of the present invention can be carried out by the method described below. (Preparation of expression cassette) The expression cassette containing an antibody gene functionally linked to a promoter region that induces gene expression in silkworm silk gland cells of the present invention can be prepared by combining a polynucleotide encoding a promoter region that induces gene expression in silkworm silk gland cells with any one of the polynucleotides selected from the above (i) to (x) by a gene recombination technique well known to those skilled in the art. The polynucleotide of the promoter region that induces gene expression in silkworm silk gland cells can be obtained, for example, by performing PCR using a promoter corresponding to the desired promoter and using genomic DNA extracted from silkworm cells as a template. For example, a method for obtaining the sericin 1 gene promoter is described in U.S. Patent Publication 2008 / 0301823.
[0033] When the expression cassette of the present invention contains an enhancer, a polynucleotide encoding the -1860 to -1127 region and / or the -5000 to -3848 region of the fibroin heavy chain gene, a polynucleotide encoding a baculovirus homologous region, a polynucleotide constituting the 5' non-translated region of baculovirus polyhedrin, and / or a polynucleotide encoding baculovirus IE1, it can be obtained by combining these polynucleotides with an antibody gene functionally linked to a promoter region that induces gene expression in silkworm silk gland cells by a method well known to those skilled in the art (for example, by using a restriction enzyme cleavage site). For example, the expression cassette of the present invention can be prepared according to the methods described in JP 2004-344123, U.S. Patent Publication No. 2008 / 0301823, JP 2008-125366, etc. (Vector Construction) The plasmid vector containing the expression cassette can be obtained by incorporating the expression cassette or its components into a desired vector. The vector is not particularly limited as long as it is a plasmid vector capable of producing transgenic silkworms, and can be produced, for example, by inserting the expression cassette into a restriction enzyme cleavage site of the above-mentioned vector. (Creation of transgenic silkworms) In one aspect, the present invention relates to a method for producing a transgenic silkworm that produces (secretes) the antibody in silk threads (cocoons) (preferably, sericin layers), comprising inserting the plasmid vector into silkworm eggs. Specifically, the method for producing a transgenic silkworm of the present invention comprises injecting the plasmid vector into silkworm eggs (silkworm embryos) 2 to 8 hours after spawning, mating the hatched adult silkworms to obtain G1 egg masses, and screening for transgenic silkworms into which the expression cassette of the present invention has been incorporated using the expression of a marker gene or the like as an indicator.
[0034] As an example, after purifying the obtained plasmid vector, it is mixed with a helper plasmid, pHA3PIG (Nat. Biotechnol. 18, 81-84 (2000)), so that the amount of plasmid is 1:1, and after further ethanol precipitation, it is dissolved in an injection buffer (0.5 mM phosphate buffer pH 7.0, 5 mM KCl) so that the DNA concentration is 10-1000 μg / ml. This vector mixture is microinjected into silkworm eggs (silkworm embryos) at the preblastoderm stage 2-8 hours after spawning, at a volume of about 1-200 nl per egg. The eggs microinjected with the vector DNA are incubated at about 25°C, the hatched silkworms are raised, and the resulting reproductive adults are mated to obtain egg masses of the G1 generation. From the G1 egg masses 3 to 10 days after spawning, transgenic silkworm eggs that emit green fluorescence from the eyes and nervous system can be selected and hatched to establish transgenic silkworms incorporating antibody cDNA.
[0035] In addition, a polynucleotide for enhancing gene expression may be introduced into the transgenic silkworm of the present invention separately from the expression cassette of the present invention. For example, a polynucleotide for enhancing gene expression may be incorporated into a plasmid vector different from the plasmid vector of the present invention, and this may be injected into silkworm eggs simultaneously or separately with the plasmid vector of the present invention. Alternatively, a transgenic silkworm into which the expression cassette of the present invention and a polynucleotide for enhancing gene expression of the present invention have been introduced may be obtained by mating a transgenic silkworm into which the expression cassette of the present invention obtained by the above-mentioned method has been incorporated with a transgenic silkworm into which a polynucleotide for enhancing gene expression has been incorporated. For example, a silkworm having both the antibody cDNA and the ie1 gene may be selected from the obtained G2 generation silkworms by mating the obtained transgenic silkworm with the expression cassette of the present invention incorporated therein (JP Patent Publication No. 2012-182995) that expresses the ie1 gene, which is a transactivator derived from BmNPV. (Antibody manufacturing method) In another aspect, the present invention relates to a method for producing an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO: 7 and a light chain having the amino acid sequence set forth in SEQ ID NO: 9, or an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO: 11 and a light chain having the amino acid sequence set forth in SEQ ID NO: 13, the method comprising extracting the antibody from silk produced by the transgenic silkworm.
[0036] For example, to produce an antibody, the silkworms are raised to produce cocoons. The silkworm cocoons are immersed in an extraction buffer (PBS (final concentration 0.5 M NaCl), 0.1% TritonX-100) and stirred at room temperature for 1 hour to prepare a cocoon extract. The extract is filtered through a 0.45 μm filter and subjected to a Protein G column (Protein G Sepharose 4 Fast Flow, GE Healthcare). The antibody can be obtained by eluting with 0.1 M glycine (pH 2.7), neutralizing the solution by adding 1 M Tris-HCl (pH 9.0), and finally dialysis against PBS.
[0037] Furthermore, antibody fragments can be prepared by various methods well known to those skilled in the art, for example, by treating the antibody obtained by the above-mentioned method with papain.
[0038] In addition, antibodies not bound to fucose can be produced in silkworm cocoons as described above, or by using cells exhibiting reduced fucosylation selected by killing cells with high fucose from CHO cells treated with a drug (US Patent Publication No. 2010 / 0081150), by using a CHO cell line with reduced fucosylation due to mutation of the Fx protein and by controlling the supply of an external source of fucose (US Patent Publication No. 2010 / 0304436), by using GMD knockout cells and FUT8 knockout host cell lines with genomic deletions corresponding to the GMD exon 5, 6 and 7 regions (KANDA, Y. et al. (2007) J. BIOTECHNOL; 130(3): 300-10), or by using four types of lectin-resistant CHO mutant cells induced by incubation with N-methyl-N-nitrosoguanidine (RIPKA, J. et al. (1986) SOMAT CELL MOL GENET;12(1):51-62), a method for producing lectin by Lec13 (fucose-deficient CHO) cell line (SHIELDS,RL et al. (2002) J BIOL CHEM;277(30):26733-40), a method for producing lectin by inducing Aleuria aurantia lectin (AAL) or Aspergillus oryzae lectin (Aspergillus oryzae lectin) in a population of CHO cells after methotrexate (MTX) treatment (SHIELDS,RL et al. (2002) J BIOL CHEM;277(30):26733-40), Known methods include a method of contacting an antibody with a non-toxic fucose-binding agent of A. oryzae 1-fucose-specific lectin (AOL) and removing cells bound to the fucose-binding agent to produce the antibody using the cells obtained (WO2012 / 120500), a method of cleaving a glycan from an antibody once and then rebinding a non-fucose-bound glycan to the antibody (JP Patent Publication 2016-082962), and a method of producing the antibody using cells expressing acetylglucosaminyltransferase III (U.S. Patent No. 6,602,684). The antibody of the present invention may be produced by any of these methods or other known antibody production methods not described herein that reduce the amount of fucose binding. 2. Pharmaceutical Compositions The antibody of the present invention can be used as a pharmaceutical composition in an oral dosage form or a parenteral dosage form such as injections, drip infusions, etc. When administered to mammals, the pharmaceutical composition may be in an oral dosage form such as tablets, powders, granules, syrups, etc., or in a parenteral dosage form such as injections, drip infusions, etc.
[0039] The pharmaceutical composition of the present invention can be formulated by conventional methods using a conventional pharma- ceutical acceptable carrier. When preparing a solid oral preparation, an excipient and, if necessary, a binder, disintegrant, lubricant, etc. are added to the main drug, and then the mixture is made into a solvent, granules, powder, capsule, etc. by conventional methods. When preparing an injection, a pH adjuster, buffer, stabilizer, solubilizer, etc. are added to the main drug as necessary, and the mixture can be made into a subcutaneous or intravenous injection by conventional methods.
[0040] In another aspect, the present invention relates to a method for treating or preventing HIV infection, comprising administering an effective amount of the antibody of the present invention to a patient in need thereof. Alternatively, the present invention relates to the use of the antibody of the present invention for producing a therapeutic or preventive drug for HIV infection. The dosage of the antibody of the present invention when administered to a mammal or the like varies depending on symptoms, age, sex, body weight, administration form, etc., but for example, when administered intravenously to an adult, the single dose can usually be 0.1 to 10,000 mg. Preferably, the administration method is capable of maintaining blood HIV below the detection limit for a long period after administration (for example, 12 weeks or more, 16 weeks or more, 20 weeks or more, 24 weeks or more, 28 weeks or more, 32 weeks or more, 36 weeks or more, 40 weeks or more, 1 year or more, 2 years or more, 3 years or more, 4 years or more, or 5 years or more). In order to confirm whether blood HIV can be maintained below the detection limit after administration, the amount of HIV in blood (for example, HIV RNA amount) may be monitored during and after the administration period, as necessary. The antibody of the present invention can be administered to an HIV-infected patient, for example, 1 to 10 times, 1 to 8 times, 1 to 5 times, 1 to 4 times, 1 to 3 times, 1 to 2 times, 1 time, 2 times, or 3 times in total. The administration interval can be 3 to 30 days, 3 to 15 days, 4 to 10 days, 5 to 9 days, 6 to 8 days, or 7 days.
[0041] Below, examples are shown to explain the present invention in more detail, but the present invention is not limited thereto. The documents cited throughout this specification are incorporated herein by reference in their entirety. This application also claims priority from Japanese Patent Application No. 2018-203114, filed on October 29, 2018. The contents of Japanese Patent Application No. 2018-203114, from which this application claims priority, are all incorporated herein by reference in their entirety. EXAMPLES
[0042] (1) Vector construction The 1C10 heavy chain cDNA was amplified by PCR using a plasmid (pMPE-1C10) incorporating the cDNA of the heavy chain (sequence number 6) and light chain (sequence number 8) of the 1C10 antibody as a template, a mixture of a primer (NruI-BmNPV-ATG) containing the restriction enzyme NruI recognition sequence and the 5' untranslated region sequence of BmNPV polyhedrin (JP Patent Publication No. 2008-125366), and a primer (Hc-F) consisting of the 5'-end sequence of the 1C10 heavy chain as a forward primer, and a primer (C-hIgG1-NruI-XhoI) consisting of the 3'-end sequence of the heavy chain to which the restriction enzymes NruI and XhoI recognition sequences have been added as a reverse primer.
[0043] The amplified fragment was treated with XhoI and inserted into a cloning vector (pCR-MCS) that had been treated with EcoRV and XhoI. Similarly, PCR was performed using the plasmid (pKVA2-1C10) containing the 1C10 light chain cDNA as a template, a mixture of NruI-BmNPV-ATG and a primer (LcK-F) consisting of the 5'-terminal sequence of the light chain as a forward primer, and a primer (LcK-R) consisting of the 3'-terminal sequence of the light chain to which the restriction enzymes NruI and XhoI recognition sequences had been added as a reverse primer, to amplify the 1C10 light chain cDNA, and the resulting fragment was inserted into pCR-MCS. (forward primer) NruI-BmNPV-ATG 5'-ATCGCGAAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAATATG-3' (SEQ ID NO: 1) Hc-F 5'-GTAATAAAAAAACCTATAAATATGGACTGGACCTGGAGGATC-3' (SEQ ID NO: 2) LcK-F 5'-GTAATAAAAAAACCTATAAATATGGTGTTGCAGACCCAGGTC-3 (SEQ ID NO: 4) (reverse primer) C-hIgG1-NruI-XhoI 5'-CGCTCGAGTCGCGATTATTTACCCGGAGACAGGGAGAG-3' (SEQ ID NO: 3) LcK-R 5'-CGCTCGAGTCGCGATTAACACTCTCCCCTGTTGAAGCTC-3' (SEQ ID NO:5) pCR-MCS, into which the 1C10 light chain cDNA had been incorporated, was cleaved with NruI to excise the light chain cDNA, which was then incorporated into a vector for producing transgenic silkworms (pMSG3.1MG, JP 2012-182995) that had been treated with Aor51HI. Next, this vector was digested with NruI and ligated with the heavy chain cDNA excised with NruI from pCR-MCS, into which the 1C10 heavy chain cDNA had been incorporated. In the resulting vector (1C10 / pMSG3.1MG), the 1C10 heavy and light chain cDNAs were each incorporated downstream of the sericin 1 promoter.
[0044] Using a similar method, we also prepared vectors for producing transgenic silkworms by incorporating the heavy and light chains of 1D9 (heavy chain cDNA sequence: sequence number 10; light chain cDNA sequence: sequence number 12) and 49G2, which are anti-HIV human antibodies derived from the same patient from which 1C10 was isolated, as well as VRC01 (Science. 329, 856-61 (2010)) and PGT121 (Nature. 477, 466-470 (2011)), which are human antibodies derived from other HIV patients, into pMSG3.1MG. (2) Creation of transgenic silkworms After purifying 1C10 / pMSG3.1MG with a Plasmid Midi Kit (QIAGEN), it was mixed with the helper plasmid pHA3PIG (Nat. Biotechnol.; 18: 81-84 (2000)) in a 1:1 ratio, and after ethanol precipitation, it was dissolved in injection buffer (0.5 mM phosphate buffer pH 7.0, 5 mM KCl) to a DNA concentration of 200 μg / mL. This vector mixture was microinjected into 383 preblastoderm stage silkworm eggs (silkworm embryos) 2 to 8 hours after oviposition, at a volume of approximately 15 to 20 nL per egg.
[0045] When eggs microinjected with vector DNA were incubated at 25°C, 85% of the eggs hatched. These silkworm larvae were reared and the grown adults were mated to obtain G1 generation eggs from 72 plots (egg masses laid by adult females). G1 egg masses 5-6 days after laying were observed under a fluorescent stereomicroscope, and egg masses from 31 plots, including transgenic silkworm eggs that emitted green fluorescence from the eyes and nervous system, were obtained. The eggs were hatched and reared, and 48 transgenic silkworms were established. Cocoon proteins were extracted from these and analyzed by SDS-PAGE. Genomic DNA was also extracted from the adults and subjected to Southern blotting. From these analyses, six lines of transgenic silkworms were selected in which the 1C10 antibody was expressed in the cocoons and one copy of the recombinant gene was carried in the genome.
[0046] The above transgenic silkworms were crossed with silkworms expressing the ie1 gene, a transactivator derived from BmNPV (JP Patent Publication 2012-182995). The IE1 protein synthesized from the ie1 gene is known to act on the hr3 enhancer and sericin 1 promoter derived from BmNPV contained in pMSG3.1MG, and to increase the expression level of recombinant proteins in the middle silk gland (Biotechol. Bioeng.; 106: 860-870 (2010)). From the G2 generation silkworms obtained by crossing, silkworms carrying both the 1C10 cDNA and the ie1 gene (hereinafter referred to as the "1C10 production line") were selected, and these silkworms were bred to produce cocoons.
[0047] Similarly, we generated transgenic silkworms by microinjecting vectors carrying cDNAs of 1D9 and 49G2 derived from the same patient as 1C10, and VRC01 and PGT121 derived from other patients into silkworm eggs. We crossed these silkworms with silkworms expressing the ie1 gene to produce cocoons containing the respective antibodies.
[0048] The weight of the cocoon shell of the obtained cocoons is shown for each line of silkworms that introduced each gene (Table 1). 1C10, 1D9, VRC01, and PGT121 produced cocoons of average weight, but 49G2 did not produce any cocoons at all.
[0049] [Table 1] (3) Analysis of expression levels The amount of antibody expression was examined for 1C10, 1D9, VRC01, and PGT121 from which cocoons were obtained. 10 mg of each cocoon was immersed in 1 mL of 8 M urea, 50 mM Tris buffer pH 8.0, 0.1 M DTT, and heated at 80°C for 5 minutes to solubilize all proteins contained in the sericin layer of the silk thread (total extraction), and the results were subjected to SDS-PAGE under reducing conditions and CBB staining to compare the amount of antibody expression.
[0050] The results are shown in Figure 1A. Antibody heavy chains (H chains) and light chains (L chains) were detected in the cocoons of the four types of genetically modified silkworms. The expression level was highest in 1C10, and 1D9 and PGT121 were also relatively high, but the expression level of VRC01 was lower than these.
[0051] Next, the amount of antibody extracted from a neutral buffer solution was analyzed. 10 mg of cocoons were immersed in 1 mL of PBS (final concentration 0.5 M NaCl), 0.1% Triton X-100, stirred at room temperature for 1 hour, and then centrifuged to collect the supernatant. Proteins in the extract were analyzed by SDS-PAGE, and the amount of antibody extracted was the highest with 1C10, while the extraction rates of 1D9 and PGT121, which had relatively high expression levels, were significantly lower than those of 1C10. The amount of antibody contained in the extract was quantified using an HPLC system (Alliance HPLC System, Waters) equipped with a protein A column (HiTrap MabSelect SuRe column (0.7 × 2.5 cm; 1 mL), GE Healthcare). 300 μL of the extract prepared from each silkworm cocoon was applied to the protein A column, washed with PBS, and the bound antibody was eluted with 100 mM citric acid pH 3.0. The antibody concentration was quantified from the area of the elution peak. From these results, the amount of antibody extracted from each cocoon was calculated. As shown in Table 1, the amount of antibody that can be extracted from each 1C10 cocoon is 1.48 mg, which is approximately 3.2 times the amount of antibody extracted from 1D9 derived from the same HIV-infected patient. (4) Purification of 1C10 antibody Cocoons from the 1C10 production line were immersed in PBS (final concentration 0.5 M NaCl), 0.1% Triton X-100, and stirred at room temperature for 1 hour to prepare a cocoon extract. The extract was filtered through a 0.45 μm filter and applied to a Protein G column (Protein G Sepharose 4 Fast Flow, GE Healthcare). 0.1 M glycine-HCl buffer (pH 2.7) was used to elute the antibody from the column. 1 M The antibody was neutralized by adding Tris-HCl (pH 9.0) and finally dialyzed against PBS. The purified antibody was designated SW-1C10 and used in the following experiments. (5) Preparation of 1C10 antibodies of different origin To investigate the differences in binding and neutralizing activities depending on the origin of the antibody, we produced 1C10 antibodies of different origins: Bcell-1C10 (Virology.; 475: 187-203 (2015)), 293A-1C10 (Virology.; 475: 187-203 (2015)), and CHO-1C10.
[0052] CHO-1C10 was prepared as follows. Using the ExpiCHO Expression System Kit (ThermoFisher Scientific), ExpiCHO-S cells (included in the kit) were transfected with a plasmid (pMPE-1C10) incorporating the 1C10 cDNA. 12-14 days after transfection, the culture supernatant was collected, filtered through a 0.2 μm filter, and then bound to a Protein A column (HiTrap rProtein A FF, GE Healthcare). The antibody was eluted from the column with 50 mM glycine-HCl buffer (pH 2.39). The antibody was neutralized by adding 1 M Tris-HCl (pH 9.0) and dialyzed against PBS. The antibody solution was concentrated using PEG 6,000 (Wako), and then dialyzed twice against PBS.
[0053] (6) Binding activity measurement for HIV-1 BaL strain The binding activity of SW-1C10 and 293A-1C10 to the HIV-1 BaL strain (Science.; 253: 71-4 (1991)) was compared. First, BaL virus-infected cells were prepared. CEM.NKR-CCR5 (NKR24) cells (J Virol.; 86: 12039-52 (2012) were incubated in a suspension (1 × 10 6NKR24 cells / 50μL) and 50μL of BaL virus suspension were mixed in a 1.5mL tube and centrifuged at 1,200×g for 2 hours at room temperature. R10 medium (J Virol.; 86:12039-52(2012)) was added, and culture was started on a 24-well plate at 37℃ and 5% CO2. The NKR24 cells were introduced with a luciferase gene controlled by the HIV-1 LTR promoter (J Virol.; 86:12039-52(2012)). The luciferase activity produced by the NKR24 cells was measured using the neolite Reporter Gene Assay System (Perkin Elmer) to confirm the appropriate viral infection status.
[0054] Once the BaL-infected NKR24 cells and non-infected (normal) NKR24 cells were prepared, samples for FACS analysis were prepared (0.2% BSA / PBS was used as the reaction solution). 6 50 μL of cells adjusted to cells / mL were added to a 96-well plate (25 × 10 4 cells / tube). An equal amount of antibody solution (concentration adjusted with D-PBS(-)) was added to give a final concentration of 0.032 / 0.16 / 0.8 / 4 / 20 / 100μg / mL. After incubation at room temperature for 30-40 minutes, the plate was washed twice with reaction solution, and 50μL of APC-labeled anti-human IgG (Jackson ImmunoResearch) diluted 200-fold with reaction solution was added (operations thereafter were performed in the dark). After incubation at room temperature for 15 minutes, the plate was washed twice with reaction solution, and 100μL of 10% Formalin / PBS was added. After incubation on ice for 15 minutes, analysis was performed using BD FACS Canto II (BD Biosciences), and the binding activity was examined from the mean fluorescence intensity (MFI) of APC.
[0055] As a result, it was confirmed that both SW-1C10 and 293A-1C10 specifically bound to BaL-infected NKR24 cells and further showed antibody concentration-dependent binding activity (Table 2 and FIG. 2).
[0056] [Table 2] (7) Neutralizing activity against HIV-1 BaL strain The neutralizing activity against the HIV-1 BaL strain was compared for SW-1C10, Bcell-1C10, 293A-1C10, and CHO-1C10. Eight 5-fold antibody dilution series with a maximum concentration of 4μg / mL were prepared on a 96-well plate (100μL / well), and 50μL of BaL virus adjusted to 4,000 TCID50 / mL was added (final 200 TCID50). After incubation at 37℃ and 5% CO2 for 1 hour, TZM-bl cells (AIDS;23:897-906(2009)) were added at 1×10 5 The concentration was adjusted to cells / mL (+37.5μg / mL DEAE dextran) and 100μL was added. VC (virus control; virus and cells only) wells were also prepared as positive controls, and CC (cell control; cells only) wells were also prepared as negative controls. After culturing for 2 days at 37℃ and 5%CO2, the cells were washed with PBS, and 30μL of Luciferase Cell Lysis Buffer (Promega) was added to each well, followed by stirring for 15 minutes. 50μL of Luciferase Assay Reagent was added to a detection white plate (Coster), and 10μL of the cell lysate was added after stirring, and RLU (relative luminescence intensity) was measured using a luminometer. The infection inhibition rate (%inhibition) = {(RLU in VC)-(RLU at each antibody concentration)} / (RLU in VC) was calculated using the RLU in CC as background, and IC50 (50% inhibitory concentration) was calculated.
[0057] Table 3 shows the IC50, and Figure 3 shows the infection inhibition rate at each antibody concentration. As a result, it was confirmed that various antibodies, including SW-1C10, showed almost equal neutralizing activity.
[0058] [Table 3] (8) Glycan structure analysis According to the literature (Mol. Cellular Proteom.; 6: 1437-1445 (2007)), the glycan structures of SW-1C10 and CHO-1C10 were analyzed by the following procedure. 50 μg of purified 1C10 was reduced and alkylated in the presence of detergent, digested with trypsin, and then digested with PNGaseA to release N-glycans. Next, 50 pmol of an internal standard was added and glycoblotting was performed (this process involves capturing N-glycans, methylating the carboxyl groups, and labeling with BOA). This was subjected to mass spectrometry (MALDI-TOF-MS; Ultraflex III, positive mode), and the obtained spectrum was compared with GlycoMod Tool (http: / / web.expasy.org / glycomod / ) to estimate the structure of N-glycans. In addition, the peak areas of each peak were normalized using the peak areas of the internal standard added in advance.
[0059] The major glycan structures estimated from the obtained mass spectra and their abundance ratios are shown in Figure 4. Approximately 70.3% of core fucose-added glycans were observed in CHO-1C10, whereas no core fucose-added glycans were detected in SW-1C10. Furthermore, the glycan structure of SW-1C10 was similar to that of CHO-1C10 in that there were no glycans containing sialic acid or bisecting GlcNAc. (9) Measurement of ADCC activity In addition to SW-1C10, 293A-1C10, and CHO-1C10, we also prepared KD-247, a humanized antibody that recognizes the V3 loop of gp120, and compared their ADCC activities against the HIV-1 BaL strain.
[0060] BaL-infected NKR24 cells were prepared in the same manner as in the binding activity measurement. After the BaL-infected NKR24 cells and non-infected (Normal) NKR24 cells were prepared, samples for measuring ADCC activity were prepared (using R10 medium 10U / ml IL-2 as the reaction solution and antibody diluent). After washing three times with the reaction solution, 2.5×10 5 NKR24 cells were adjusted to 1 × 10 cells / mL and added to a 96-well plate at 40 μL. 4 After washing once with the reaction solution, 2.5 × 10 effector cells were added. 6 40 μL of human CD16+ KHYG-1 cells (N6 cells; J Virol.; 86:12039-52(2012)), a natural killer cell line, adjusted to 10 × 10 cells / mL was added. 4 Then, 20 μL of each antibody was added to give a final concentration of 0.2, 2, or 20 μg / mL. As a positive control, VC (virus control; only BaL-infected NKR24 cells and N6 cells) wells were prepared, and as a negative control, CC (cell control; only uninfected NKR24 cells and N6 cells) wells were prepared at the same time, and the wells were incubated at 37°C and 5% CO2 for 6 hours.
[0061] The neolite Reporter Gene Assay System was used to measure ADCC activity. 40 μL of neolite reagent was added to a detection white plate (Perkin Elmer), and 40 μL of the reaction solution after incubation was suspended and added, and RLU (relative light emission intensity) was measured using a Luminometer. The virus killing rate (% killing; (RLU at VC - RLU at each antibody concentration) / RLU at VC) was calculated using the RLU at CC as the background, and this was used as the ADCC activity (Figures 5A and B). As a result, it was confirmed that SW-1C10 showed the highest ADCC activity among the antibodies compared. (10) Mass production of 1C10 for animal experiments Approximately 30,000 1C10 production strains were raised at all ages on artificial feed (Nihon Nosan Kogyo Co., Ltd. Silkmate Original Seed 1-3 Age S) to produce cocoons. The cocoons were cut open with scissors to remove the pupae, and approximately 1.1 kg of cocoon shells were obtained. 1.0 kg of these was used to extract and purify SW-1C10.
[0062] One kilogram of cocoons was immersed in 100 L of extraction buffer (50 mM acetate buffer pH 5.3, 30 mM NaCl, 0.2% Triton X-100, 0.01% polydimethylsiloxane) and squeezed at 25°C for 2 hours to extract proteins. After filtration with a 10 μm industrial filter (SMC), the cocoons were loaded onto a STREAMLINE 200 Column (GE Healthcare) packed with 5 L of cation exchange carrier (STREAMLINE SP (GE Healthcare)). After washing with SP washing buffer (50 mM acetate buffer pH 5.3, 30 mM NaCl, 0.2% Triton X-100), the 1C10 antibody was recovered by elution with SP elution buffer (50 mM acetate buffer pH 5.3, 300 mM NaCl). The 1C10 antibody was then concentrated using an ultrafiltration membrane (Biomax-100 TF (Millipore)) and then solvent exchanged with PBS. This was applied to a column packed with Protein A carrier (MabSelect SuRe (GE Healthcare)), washed with PBS, and the 1C10 antibody was eluted with 100 mM citrate buffer (pH 3.0). Finally, it was concentrated using an ultrafiltration membrane and the solvent was replaced with a storage solution (10 mM acetate buffer pH 5.5, 50 mM NaCl, 100 mM arginine hydrochloride). Through the above operations, approximately 7.9 g of purified SW-1C10 with a purity of 99.0% or more was prepared. (11) Administration of 1C10 to HIV-infected cynomolgus monkeys To evaluate the efficacy of SW-1C10 during acute infection, seven cynomolgus monkeys were inoculated rectally with 50,000 TCID50 of highly virulent SHIV89.6P (Reimann KA et al., J. Virol. 70, 6922-6928.), a chimeric virus in which Env derived from HIV89.6 strain was integrated into SIV, to establish systemic infection. The cynomolgus monkeys were divided into four groups, a control group of untreated monkeys and three groups of monkeys treated with SW-1C10. SW-1C10 was administered intravenously on days 3, 10, and 17 after virus inoculation, and the suppressive effect on the blood virus level was observed.
[0063] Peripheral blood (with EDTA added) was collected periodically from anesthetized monkeys, usually every 7 days until the 8th week after virus inoculation, and once every 4 weeks thereafter. Plasma was collected from the collected blood by centrifugation, and the blood cells were then diluted with PBS, layered on Percoll with a specific gravity of 1.070, and centrifuged to separate PBMCs (peripheral blood mononuclear cells). Viral RNA was extracted from the plasma, and the gag region of SIVmac239 was amplified by quantitative RT-PCR, and the viral RNA copy number in the plasma was calculated from the concentration of the product. Viral RNA in the plasma was extracted and purified using the MagNA PureCompact Nucleic Acid isolation kit (Roche Diagnostics).
[0064] The amount of RNA was calculated using a LightCycler 480 thermocycler (Roche Diagnostics) with primers and a probe targeting the gag region of SIVmac239. Viral RNA was amplified and detected using a QuantiTec Probe RT-PCR kit (Qiagen). The following primers and templates were designed: 5'-GCAGAGGAGGAAATTACCCAGTAC-3' / SEQ ID NO: 14 as the forward primer, 5'-CAATTTTACCCAGGCATTTAATGTT-3' / SEQ ID NO: 15 as the reverse primer, and 5'-FAM-TGTCCACCTGCCATTAAGTCCCGA-TAMRA-3' / SEQ ID NO: 16 as the probe.
[0065] The amount of RT-PCR products was determined by detecting fluorescence using a LightCycler 480 thermocycler. The amount of virus in plasma was determined by measuring twice in duplicate, and the amount of virus was calculated using a standard curve prepared by serially diluting SIV RNA of known concentrations. Template DNA and other contaminating DNA were treated with DNAase I. The sensitivity of this measurement system was 100 copies / ml.
[0066] In the control untreated monkeys, the number of viral RNA copies per milliliter of plasma rose to tens to hundreds of millions of copies two weeks after virus inoculation, and then entered a steady state called the virological set point from week eight onwards, remaining at tens to hundreds of thousands of copies / ml. The number of CD4+ T cells, which are the target of HIV infection, rapidly decreased from weeks two to four, and then remained at a low level. On the other hand, in the SW-1C10-treated group, the viral load peaked at 100,000 to 1 million copies / ml four weeks after virus inoculation, then decreased, and the virus was undetectable in all three monkeys from week 12 onwards. Furthermore, the number of CD4+ T cells did not decrease significantly and remained at the level before virus inoculation (Figure 6).
[0067] Surprisingly, these results showed that in all individuals administered SW-1C10, the virus became undetectable from an early stage, and viral RNA was controlled to be below the detection limit for a long period of 12 weeks. Such long-term control of viral proliferation in all administered cases has not been reported in the past, and the inventors have succeeded in discovering for the first time an antibody that brings about widespread and stable viral control in administered subjects.
Claims
1. An IgG antibody, A heavy chain includes an amino acid sequence having several amino acids substituted, deleted, added or inserted in the amino acid sequence shown in SEQ ID NO:7, and a light chain includes an amino acid sequence having several amino acids substituted, deleted, added or inserted in the amino acid sequence shown in SEQ ID NO:9; having the ability to bind to HIV; and An antibody in which the glycan that binds to the antibody does not contain fucose.
2. A composition comprising an IgG antibody capable of binding to HIV, A composition, wherein 80% or more of the IgG antibodies are the antibodies described in claim 1.
3. An expression cassette comprising any one of the following polynucleotides (i), (iii) and (v) operably linked downstream of a silk gland-specific gene promoter: (i) a polypeptide having the nucleotide sequence set forth in SEQ ID NO: 6 and / or the nucleotide sequence set forth in SEQ ID NO: 8; nucleotide; (iii) a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 7, and / or a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO: 9; (v) A polynucleotide encoding a heavy chain comprising an amino acid sequence in which several amino acids have been substituted, deleted, added or inserted in the amino acid sequence set forth in SEQ ID NO:7, and / or a polynucleotide encoding a light chain comprising an amino acid sequence in which several amino acids have been substituted, deleted, added or inserted in the amino acid sequence set forth in SEQ ID NO:9, wherein an IgG antibody having the heavy chain and the light chain has the ability to bind to HIV.
4. The expression cassette of claim 3 , wherein the promoter region is a sericin 1 promoter, a sericin 2 promoter, or a sericin 3 promoter.
5. A plasmid vector comprising the expression cassette according to claim 3 or 4.
6. A method for producing a transgenic silkworm, comprising inserting the plasmid vector according to claim 5 into an egg of a silkworm.
7. A transgenic silkworm having the expression cassette according to claim 4 integrated into its chromosome.
8. A method for producing an antibody, comprising extracting the antibody from silk produced by the transgenic silkworm described in claim 7.
9. A pharmaceutical composition for treating or preventing HIV, comprising the antibody according to claim 5 or the composition according to claim 2 as an active ingredient.
10. The pharmaceutical composition according to claim 9, for administration 1 to 5 times after HIV infection.
11. The pharmaceutical composition according to claim 9, which is administered two or more times, with the second or subsequent administration being administered 3 to 30 days after the previous administration.
Citation Information
Patent Citations
Method for producing glycoprotein having characteristic sugar chain structure by using silkworm
JP2014012024A
Anti-hiv monoclonal antibody
WO2009066702A1
